Stevanato Group
STVN Mid CapHealthcare · Medical Instruments & Supplies
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Stevanato Group en bref
Stevanato Group (STVN) is currently trading at 15,35 € with a market capitalization of 4,2 Md €. The trailing P/E ratio stands at 29.81x, with a forward P/E of 20.99x. The 52-week range spans from 11,25 € to 24,43 €; the current price is 37.2% below the yearly high. Year-over-year revenue growth stands at +6.6%. The net profit margin stands at 11.75%.
💰 Dividende
Stevanato Group currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
10 analystes évaluent Stevanato Group (STVN) au consensus : Acheter. L'objectif de cours moyen est de 21,69 €, soit un potentiel de +41.28% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 15,27 € à 27,93 €.
Stevanato Group : la thèse d'investissement en détail
Stevanato Group (STVN) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in Italy. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Wall Street consensus sits at Buy with an average price target implying roughly 41.28% upside from current levels — analyst sentiment is firmly constructive.
Valorisation en contexte
At a PEG of 3.57, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.
À surveiller
- The forward P/E of 20.99x is meaningfully below the trailing 29.81x — analysts expect earnings to step up; the next earnings release is the test.
- The analyst consensus price target implies 41.28% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 29.43)
- –Free cash flow négatif
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to relatively defensive market behavior.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Stevanato Group?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
